The CEO continued: “The decision to approve the new drug is a reminder that there are safe, effective therapies and treatment options available to help prevent fractures and enable people to live well with the disease. Osteoporosis.”
Still, Jones said there are still some issues to work out: “The next important step is to end the postcode lottery for fracture communication services, which remains a difficult barrier to viability. timely diagnosis and treatment of people.
“Closing the visual treatment gap for osteoporosis depends on ending inequalities in local services across the NHS.”
Meanwhile, osteoporosis is more likely to occur in later life because “you gradually start to lose bone from around age 35”, the NHS said.
Source: | This article first appeared on Express.co.uk
